The report gives high rankings to brands from Pfizer and AstraZeneca.
Trinity Life Sciences released its annual TGaS Digital Marketing Competency Report.1 The fourth edition of this report provides an analysis of various brands and their presence across digital platforms. TGaS is a division of Trinity Life Sciences.
In a press release, TGaS VP of omnichannel marketing Jerry Luciano said, “The digital space is evolving at a faster pace than ever before, with more brands integrating digital-first strategies to better connect with patients and caregivers. Over the past four years of conducting the study, we have observed an acceleration across the industry in driving an improved customer experience through digital.”
The following brands topped the 2024 report: Nurtec by Pfizer, Breztri by AstraZeneca, Slynd by Exeltis, and Opzelura by Incyte. The report includes 157 total rankings, and ranks each brand on a scale from “transformational” to “novice.”
Trinity also recently released a report measuring the impact of field medical affairs in late November.2 In that area, the company also noted that a transformational approach was beneficial.
In a press release issued at the time, Trinity Life Sciences managing director of medical affairs Khalil Ahmed said, “There is an impetus among leadership to understand the return on investment and overarching impact that Field Medical Affairs has on the organizational goal and mission. The most effective way to demonstrate value is to choose KPIs that drive HCP perception, improve quality of care and clinical practice and have a positive impact on patients’ lives.”
TGaS Advisors vice president of medical affairs Sarah Odeh added, “We keep a strong pulse on industry trends and best practices, and we’re seeing many examples of leaders innovating and thinking about demonstrating impact for their Field Medical Affairs teams. We’re excited to support our clients through this transformation and help them build a best-in-class Field Medical Affairs program.”
Also in November, Trinity announced that Frank Lane would serve as senior vice president and head of data orchestration at TrinityEDGE, the company’s commercial data strategy, insights, and analytics firm.3
In a press release issued at the time, Lane said, “Many life science companies have become data rich and insights poor due to the lack of sophisticated data orchestration and the challenges to use technology to turn data into actionable insights,” said Frank Lane, Senior Vice President and Head of Data Orchestration at Trinity Life Sciences. “The pharmaceutical data ecosystem is complex and requires specialized capabilities to harness the power of data to drive customer engagement strategies, guide tactical sales and marketing activities and enable collaboration across business functions to best serve the market.”
In the same press release, Trinity Life Sciences’ head of analytics and insights Aparna Deshpande said, “In order to enable data and analytics to drive performance in a comprehensive way, life science companies need two things: 1) a seamless plan that focuses on end-to-end digital journeys rather than isolated projects and 2) a purpose-built platform created and supported by biopharmaceutical experts that takes into consideration the commercial functions, needs, data nuances and technology applications specific to life science companies. We are pleased that we can offer the industry both of these key components to ensure successful data orchestration.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.